SPOTLIGHT: Lymphoma drugs often avoided


Only a fraction of the patients who could benefit from lymphoma drugs like Bexxar and Zevalin actually get them, largely because doctors get reimbursed on other therapies or are reluctant to refer patients to competing academic centers. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.